Biospecifics Technologies (BSTC) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	8.46M
Depreciation and amortization	1.22M
Stock-based compensation expense	100.43K
Accounts receivable	-1.3M
Deferred tax assets	-2.75M
Prepaid expenses and other current assets	-170.59K
Accounts payable and accrued expenses	380.86K
Deferred revenue	7.67M
Net cash provided by (used in) operating activities
Proceeds from stock option exercises	529.3K
Payments for repurchase of common stock	-898.03K
Excess tax benefits from share-based payment arrangements	224.05K
Net cash provided by (used in) financing activities
Increase (decrease) in cash and cash equivalents	-390.13K
Cash and cash equivalents at beginning of year	5.14M
Cash and cash equivalents at end of period	4.75M
Interest	0
Taxes	5.83M

Entities mentioned with BSTC

View All Entities